Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes.

By Shelley Lindley, C. Dayan, A. Bishop, B. Roep, M. Peakman, T. Tree. Diabetes, 2005

885 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. (2008, neutral): “Studies of Treg cell dynamics in human T1D patients have produced disparate results, ranging from reduced Treg cell frequency (Kukreja et al., 2002) or function (Brusko et al., 2005; Lindley et al., 2005 ) to no changes when comparing diabetic subjects to healthy control subjects (Putnam et al., 20”
The PD-1 Pathway in Tolerance and Autoimmunity (2010, background): “Furthermore, effector T cells from T1D individuals may be intrinsically defective.”
Rapamycin Promotes Expansion of Functional CD4+CD25+FOXP3+ Regulatory T Cells of Both Healthy Subjects and Type 1 Diabetic Patients1 (2006, background): “(22) that CD4 CD25 T cells are reduced in T1D subjects, it is now ascertained that the frequency of CD4 CD25 /bright T cells in T1D patients is similar to that of healthy controls (12, 13, 23).”